Clinical Trial

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-21; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2025-04-14
Trial Details
NCT Number NCT06842199
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Plaque Psoriasis Patients
Enrollment 383 participants
Start Date 2025-03-20
Primary Completion 2026-05 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-09